Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine

Human Psychopharmacology

Volumn 15, Issue 6, 2000, Pages 453-459

  Charlier, C ^a   Pinto, E ^a   Ansseau, M ^a   Plomteux, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Clinical effect; Depression; Dose response relationship; Drug interactions; Plasma concentration

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; PAROXETINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0033817411     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1077(200008)15:6<453::AID-HUP228>3.0.CO;2-F     Document Type: Article

References (20)

1. Treatment-resistant depression
2. Apports et limites des dosages plasmatiques d'antidepresseurs
3. Fluoxetine: Relationships among dose, response adverse events, and plasma concentration in the treatment of depression
4. Minimum effective dose for antidepressants - An obligatory requirement for antidepressant drug evaluation
5. Le controle therapeutique des medicaments antidepresseurs
6. Monitoring of tricyclic antidepressant plasma levels and clinical response: A review of literature. Part I
7. Compliance during treatment with antidepressants
8. Efficacy issues with anti-depressants
9. Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors
10. Pharmacokinetic optimisation of therapy with newer antidepressants
11. Target concentration intervention: Beyond Y2K
12. Fluoxetine and norfluoxetine concentrations and anti-depressant response
13. Antidepressants and drug metabolizing enzymes - Expert group report
14. A new depression scale designed to be sensitive to change
15. Side effects, dropouts from treatment and cost consequences
16. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone and mirtazapine
17. Serotonin reuptake inhibitors and the adequacy of antidepressant treatment
18. When at first you don't succeed: Sequential strategies for antidepressant non-responders
19. Therapeutic and toxic drug concentrations